Abstract:Abstract Apart from EGFR T790M mutation, the bypass activation of c-Met and Axl kinase also can lead to the resistance to tyrosine kinase inhibitors (TKIs) in NSCLC. Axl and c-Met share same downstream pathways with EGFR, thus combined treatments of EGFR inhibitors with Axl or Met inhibitor are promising to overcome acquired resistance of TKIs. Our previous work showed that the water extract of Marsdenia tenacissima (MTE), which used to treat cancer in clinics for decades, restored gefitinib sensitivity in resistant NSCLC cells with EGFR T790M mutation or K-ras mutations in vitro and in vivo. However, the potential effeicacy of MTE on Axl and c-Met mediated resistance has not yet been fully understood, and the related molecular mechanisms also need to be elucidated. The present study was performed on HCC827/ER cells, which was established by exposing parental HCC827 cells to erlotinib. HCC827/ER cells are with Axl activiation and c-Met amplification, and show dual-resistance to erlotinib and gefitinib. We evaluated the effects of MTE to restore erlotinib/gefitinib sensitivity with three different combinations. Cell viability and cell apoptosis were determined by MTT and flow cytometry, respectively. The c-Met amplification was assessed with TaqMan real-time PCR. Signaling pathways were examined by Western blotting to reveal the possible mechanisms. The in vivo effects of MTE combined with erlotinib/gefitinib were tested on HCC827/ER xenograft mice, and tumor tissues were subjected to immunohistochemistry analysis and Western blotting. Our results indicated the MTE→MTE+Erlotinib/Geftinib (M→M+E/G) treatment was the most potent combinations. Compared with control group and each single, M→M+E/G treatment induced significant apoptosis, obviously inhibited EGF-induced phosphorylation of PI3K/Akt/mTOR and ERK1/2, down-regulated HGF/c-Met activation in HCC827/ER cells. Axl is a receptor tyrosine kinase which strongly associated with EMT phenotype. The M→M+E/G treatments could not restrain Axl expressions but remarkably reduced phospho-Axl levels and inhibited EMT phenotype in HCC827/ER cells. Surprisingly, MTE alone caused prominent p-Axl inhibition, along with up-regulated E-cadherin and decreased mesenchymal markers. The mouse tumors were remarkably restrained by the M→M+E/G combinations, and it was significant compared with each drug alone (P<0.05). Accordingly, cell apoptosis was extended, PCNA expression and tumor angiogenesis (VEGF and CD105) were reduced and EMT phenotype were regulated in tumor tissues. The p-Met and p-AXL were also considerably suppressed by the combined treatments. The present data revealed that MTE restored TKIs such as erlotinib and gefitinib efficacy in resistant NSCLC cells with Axl activation and c-Met amplification in vitro and in vivo. It suggests that the addition of MTE may be a promising therapeutic strategy to overcome TKIs resistance in NSCLC. Citation Format: Shu-Yan Han, Hong Sun, Dong Xue, Wei Zhao, Yan-Na Jiao, Ping-Ping Li. Overcomes AXL and Met mediated erlotinib/gefitinib cross resistance in non-small cell lung cancer cells by Marsdenia tenacissima extract [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1199. doi:10.1158/1538-7445.AM2017-1199

Marsdenia Tenacissima Extract Overcomes Axl- and Met-mediated Erlotinib and Gefitinib Cross-Resistance in Non-Small Cell Lung Cancer Cells

Abstract 1199: Overcomes AXL and Met Mediated Erlotinib/gefitinib Cross Resistance in Non-Small Cell Lung Cancer Cells Bymarsdenia Tenacissimaextract

Abstract 1199: Overcomes AXL and Met mediated erlotinib/gefitinib cross resistance in non-small cell lung cancer cells by<i>Marsdenia tenacissima</i>extract

Marsdenia Tenacissima Extract Restored Gefitinib Sensitivity in Resistant Non-Small Cell Lung Cancer Cells.

Marsdenia Tenacissima Extract Enhances Gefitinib Efficacy in Non-Small-Cell Lung Cancer Xenografts

Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.

Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity

Concurrent Use of Metformin Enhances the Efficacy of EGFR-TKIs in Patients with Advanced EGFR-mutant Non-Small Cell Lung Cancer—an Option for Overcoming EGFR-TKI Resistance

Combined Treatment Withepimedium Koreanumnakai Extract and Gefitinib Overcomes Drug Resistance Caused by T790M Mutation in Non-Small Cell Lung Cancer Cells

Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer

Marsdenia tenacissima extract induces apoptosis and suppresses autophagy through ERK activation in lung cancer cells

Antitumor Activity of Selective MEK1/2 Inhibitor AZD6244 in Combination with PI3K/mTOR Inhibitor BEZ235 in Gefitinib-Resistant NSCLC Xenograft Models

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway

Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib

Targeting a Novel COX2/MET/TOPK Signaling Axis Overcomes Gefitinib Resistance in NSCLC

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Suppression of C-Met Overcomes Erlotinib Resistance in Tongue Cancer Cells

Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells

Methylseleninic Acid Overcomes Gefitinib Resistance Through Asparagine-Met-topk Signaling Axis in Non-Small Cell Lung Cancer Cells.

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells